Q-omics provides the consensus-scored SPRYD3 profile across patient tissues and cancer cell-line models. SPRYD3 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, SPRYD3 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, SPRYD3 RNA expression shows 19,209 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, COAD, and ACC as cancer lineages where SPRYD3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPRYD3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPRYD3 survival associations across molecular data types. SPRYD3 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPRYD3 RNA expression–survival associations across cancer types. High SPRYD3 expression shows unfavorable associations in HNSC, LIHC and LAML, but favorable associations in KIRC, THCA and LGG. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for SPRYD3 RNA expression.
This table summarizes SPRYD3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SPRYD3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPRYD3 shows lower tumor expression in BLCA, LUAD and UCEC and higher tumor expression in COAD, HNSC and LIHC. The COAD box plot shows higher SPRYD3 RNA expression in tumor versus normal tissue (log2 FC = +0.565, t-test p < 0.001).
This table shows molecular features associated with SPRYD3 in patient tissues and cancer cell lines. In patient samples, SPRYD3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SPRYD3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Lymphoma.
